Immunogenicity of the abbreviated one-week intradermal rabies pre-exposure prophylaxis and its boostability in health-care workers: A retrospective observational cohort study

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-09-27 DOI:10.1016/j.vaccine.2025.127787

M.A. Ashwini, Shipra Gupta, Lonika Lodha, Arya Ramachandran , Amrita Pattanaik , V.S. Sujatha, Reeta S. Mani

{"title":"Immunogenicity of the abbreviated one-week intradermal rabies pre-exposure prophylaxis and its boostability in health-care workers: A retrospective observational cohort study","authors":"M.A. Ashwini, Shipra Gupta, Lonika Lodha, Arya Ramachandran , Amrita Pattanaik , V.S. Sujatha, Reeta S. Mani","doi":"10.1016/j.vaccine.2025.127787","DOIUrl":null,"url":null,"abstract":"<div><div>Rabies pre-exposure prophylaxis (PrEP) is recommended for those at high occupational risk, including health care workers (HCWs) in rabies-endemic settings. Following institutional biosafety protocols, HCWs receive a one-week, two-site intradermal (ID) PrEP regimen. This retrospective vaccination records review assessed the immunogenicity of this regimen following primary vaccination and evaluated the immune response to a booster dose administered 1–3 years later. 92 HCWs with mean baseline rabies virus neutralizing antibody (RVNA) titres of 0.13 IU/mL showed adequate seroconversion (RVNA ≥ 0.5 IU/mL) by day 14, with mean titre of 13.40 IU/mL. 39 HCWs with mean pre-booster titre of 2.76 IU/mL received a booster 1–3 years later and mean post-booster titres were 51.13 IU/mL, indicating a strong anamnestic response. The regimen elicited robust seroconversion in all HCWs and induced a strong secondary immune response, supporting the immunogenicity and long-term boostability of this shortened regimen in high-risk occupational settings.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127787"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25010849","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Rabies pre-exposure prophylaxis (PrEP) is recommended for those at high occupational risk, including health care workers (HCWs) in rabies-endemic settings. Following institutional biosafety protocols, HCWs receive a one-week, two-site intradermal (ID) PrEP regimen. This retrospective vaccination records review assessed the immunogenicity of this regimen following primary vaccination and evaluated the immune response to a booster dose administered 1–3 years later. 92 HCWs with mean baseline rabies virus neutralizing antibody (RVNA) titres of 0.13 IU/mL showed adequate seroconversion (RVNA ≥ 0.5 IU/mL) by day 14, with mean titre of 13.40 IU/mL. 39 HCWs with mean pre-booster titre of 2.76 IU/mL received a booster 1–3 years later and mean post-booster titres were 51.13 IU/mL, indicating a strong anamnestic response. The regimen elicited robust seroconversion in all HCWs and induced a strong secondary immune response, supporting the immunogenicity and long-term boostability of this shortened regimen in high-risk occupational settings.

查看原文本刊更多论文

卫生保健工作者暴露前1周皮内狂犬病简略预防的免疫原性及其增强性：一项回顾性观察队列研究

建议对职业风险高的人员，包括狂犬病流行环境中的卫生保健工作者采取狂犬病暴露前预防措施。按照机构生物安全方案，卫生保健工作者接受为期一周的两个部位皮内（ID） PrEP方案。这项回顾性疫苗接种记录回顾评估了初次接种后该方案的免疫原性，并评估了1-3年后给予加强剂量的免疫反应。92只基线狂犬病毒中和抗体（RVNA）平均滴度为0.13 IU/mL的HCWs在第14天显示出足够的血清转化（RVNA≥0.5 IU/mL），平均滴度为13.40 IU/mL。39例HCWs平均强化前滴度为2.76 IU/mL， 1-3年后接受强化治疗，平均强化后滴度为51.13 IU/mL，表明有较强的遗忘反应。该方案在所有HCWs中引发了强大的血清转化，并诱导了强烈的二次免疫反应，支持了这种缩短方案在高风险职业环境中的免疫原性和长期增强性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.